On Rare Disease Day, Ultragenyx's Head of Gene Therapy Research explains the company's Rare Disease Bootcamp that helps families navigate drug development, and he also talks gene therapy science

Matthew Fuller describes the course that Ultragenyx will be holding both in the Bay Area and Massachusetts. He also explains the improvements in vector delivery capabilities, and improving the yield and lowering the cost of future treatments, that is possible with the latest generation of gene therapy.